AI-driven drug targets with improved clinical success

Purpose and goal

This project enhances Precisium AI’s drug target identification platform, which integrates single-cell, spatial, and bulk omics data from over 600 million cells to model gene and protein behavior in disease. Focusing on inflammatory diseases (ulcerative colitis, Crohn’s, COPD, and lupus) it aims to validate predictive accuracy, expand target discovery, and improve clinical success rates in early drug development.

Expected effects and result

The project will deliver a validated AI-driven platform capable of accurately predicting high-confidence drug targets with improved clinical success potential. Expected results include benchmarked target reports, verified model performance, and a scalable workflow ready for commercialization and collaboration with pharmaceutical and biotech partners.

Planned approach and implementation

The project will be executed in four work packages: coordination, platform scaling, report generation, and market strategy. It will refine AI models, integrate large-scale multi-omics data, perform virtual perturbation analyses, and generate benchmarked target reports. Commercial tasks include stakeholder validation, pricing models, and go-to-market planning for pharma engagement.